window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Advanced Therapies,Biotech & Pharma Business,Research & Development

    Circio raises NOK 200M (€18.6M) to advance in vivo CAR-T programme

    Circio has raised approximately NOK 200M (€18.6M) to advance its [...]

    September 15, 2026
  • Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    AstraZeneca advances oral COPD drug into Phase 2b trial

    AstraZeneca is evaluating its oral IRAK4 inhibitor AZD6793 in a [...]

    September 15, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Medical devices,Research & Development

    Fuse Diagnostics raises £1M to scale rapid molecular testing platform

    Fuse Diagnostics has raised £1 million to scale manufacturing and [...]

    September 15, 2026
  • Central Nervous System,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Amyl Therapeutics raises €8.25M to advance pan-amyloid neurodegenerative disease platform

    Amyl Therapeutics has raised €8.25m to generate preclinical data for [...]

    September 14, 2026
  • Clinical & Regulatory,Digital & Data,Research & Development

    CluePoints brings AI-powered clinical data review to DPHARM 2026

    AI and Robust Scientific Foundations to Optimize Clinical Trial Operations [...]

    September 16, 2026
  • Digital & Data,Drug Discovery & Development,Research & Development

    NVision deploys quantum-enhanced MRI platform at Hokkaido University

    NVision has deployed its POLARIS quantum-enhanced MRI platform at Hokkaido [...]

    September 14, 2026
  • Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    L-glutamine shows 44% response rate in Phase 1 pancreatic cancer trial

    L-glutamine combined with chemotherapy produced a 44% response rate in [...]

    September 14, 2026
  • Drug Delivery & Formulation,Manufacturing & Supply Chain,Research & Development

    Evonik invests €93M in new GMP LNP manufacturing facility

    Evonik is investing more than €93m in a new GMP [...]

    September 14, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Kazia reports 83% response rate for paxalisib in triple-negative breast cancer

    Early Phase 1b data show five objective responses among six [...]

    September 14, 2026
  • Central Nervous System,Drug Discovery & Development,Research & Development,Therapeutic Areas

    $3M funding targets tau-driven neurodegenerative diseases

    A $3m research programme will fund four projects investigating the [...]

    September 14, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Lifebit awarded three-year NIHR BioResource research environment contract
    Categories: Biotech & Pharma Business, Digital & Data, Research & Development
  • Resolution Therapeutics partners with Blood Centers of America for RTX001 programme
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
  • Researchers develop human iPS cell model of heart failure
    Categories: Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top